Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized observer-blind placebo-controlled study of mRNA-1647 CMV vaccine in healthy women of childbearing potential
MOH_2022-04-14_010741Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of mRNA-1647 in cytomegalovirus disease (CMV) and congenital cytomegalovirus infection (cCMV) (4 cohorts), sponsored by Moderna Inc. Started Apr 2022; status: completed.
02
Drugs
mRNA-1647
03
Conditions
cytomegalovirus disease (CMV)congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on MOH_2022-04-14_010741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-04-14_010741.